Major mutations found in NSCLC are as follows: Kirsten rat sarcoma viral oncogene homolog, KRAS, gene mutations (15–30%); epidermal growth factor receptor, EGFR, gene mutations (10–35%); anaplastic lymphoma kinase, ALK, and ROS-1 gene rearrangement (3–7% and 1–3%, respectively); BRAF mutation (1–5%); neurotrophic tyrosine receptor kinase, NTRK, fusion (0.2–3%); MET mutation or amplification (2–4%); RET mutation or fusion (0.6–1%); and human epidermal growth factor receptor-2, HER2, mutation (2–5%) [1,16,20,23,24]. Here, ALK is linked to non-small cell lung carcinoma.